Tikehau IM has acted as sole lead arranger of a EUR35 million unitranche denominated in USD for the acquisition of Cisbio Bioassays by Abénex.
Abénex acquires Cisbio Bioassays in a secondary LBO from Argos Soditic. Flexible unitranche financing denominated in US$ has been arranged by Tikehau IM.
Cisbio Bioassays is a French life sciences company committed to improving human healthcare. With more than 30 years of experience in in vitro diagnostics and drug discovery, Cisbio Bioassays provides creative technological solutions by partnering with the global scientific community in Codolet (France). Its portfolio of over 460 proprietary assays and reagents is used by leading pharmaceutical and biotechnology companies, academia and contract research organizations worldwide in the pursuit of developing effective therapies.
Cisbio Bioassays is based in France with subsidiaries in the US, China and Japan and was created in 1980 as a spin-off from the CEA (Commissariat à l’Energie Atomique).